sacituzumab govitecan,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['mbc', 'sacituzumab']
at asco22 we learnt that t-dxd &amp; sacituzumab govitecan can be beneficial both in hr+ &amp; triple-negative mbc. how can we mitigate their side effects? at dfci we are currently conducting a clinical trial testing cold caps to prevent alopecia. more info here: 
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.